Jump to content

Genedata Selector Open Forum 8: Introduction by Event Co-host

In this webinar, Marco de Cecco, Director of Cytogenomics at the Astellas Institute for Regenerative Medicine, discusses AIRM’s motivation to implement NGS for characterizing and releasing cell therapy products and overcoming the limitations of traditional biosafety testing. He further emphasizes the significance of utilizing NGS for Adventitious Agent Detection (AAD) as a Critical Quality Attribute (CQA) to safeguard all GMP-manufactured cell products. Marco concludes his introduction by detailing the virtuous collaboration with Genedata Selector® and the platform's ability to integrate, analyze and share project-related data in a regulated environment for improved decision-making and speed to market. 

This talk was given as an introduction to one of our regular Open Forum events on NGS-based QC for advancing drug development and manufacturing. 

Who should watch? 

Biopharma and biotech professionals looking to advance analytical development, biosafety, and QC testing for CGT products by embracing digitalization and innovative enterprise data analysis systems. 

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy